Zoetis Inc. Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High
Zoetis Inc. (ZTS) had Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High of $25.00 million as of 2015-06-28, per its 10-Q filed 2015-08-06.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Contingent Consideration
us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh · last filed 2015-08-06
- 2015-06-28: Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $25.00M.
- 2015-03-29: Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $25.00M.
| Period end | Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |
|---|---|
| 2015-06-28 | $25.00M 10-Q · filed 2015-08-06 |
| 2015-03-29 | $25.00M 10-Q · filed 2015-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |